Seres Therapeutics to Present at CARB-X Investor Day
Seres Therapeutics announced its presentation at the 2026 CARB-X Investor Day, underscoring its ongoing collaboration with CARB-X to develop novel live biotherapeutics targeting antimicrobial resistance (AMR). The company highlighted its advancement of SER-428, an oral liquid formulation intended for ICU patients at high risk of AMR infections, sup…